1 |
1- deoxygalactonojirimycin |
- |
- |
- |
- |
019 1件: 19 💬 |
2 |
1-deoxygalactonojirimycin |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
3 |
1-deoxygalactonojirimycin hydrochloride |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
4 |
12s-it |
- |
- |
- |
- |
019 1件: 19 💬 |
5 |
15 o water |
Water |
1件: D00001 D00001 💬 |
- |
- |
019 1件: 19 💬 |
6 |
2(s)-(acetylamino)-4-methylpentanoic acid |
- |
- |
- |
- |
019 1件: 19 💬 |
7 |
2-aminoethanethiol |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 2件: 19, 299 💬 |
8 |
2-hydroxypropyl-beta-cyclodextrin |
Betadex |
1件: D02401 D02401 💬 |
- |
- |
019 1件: 19 💬 |
9 |
4d-310 |
- |
- |
- |
- |
019 1件: 19 💬 |
10 |
500 0500 0 |
- |
- |
- |
- |
019 1件: 19 💬 |
11 |
89 zirconium recombinant human alpha-n-acetylglucosaminidase (rhnaglu) (radiolabeled) |
- |
- |
- |
- |
019 1件: 19 💬 |
12 |
89zr-sbc-103 |
- |
- |
- |
- |
019 1件: 19 💬 |
13 |
[045251016] |
- |
- |
- |
- |
019 1件: 19 💬 |
14 |
[14c] at1001 |
- |
- |
- |
- |
019 1件: 19 💬 |
15 |
[a16ab04] |
- |
- |
- |
- |
019 1件: 19 💬 |
16 |
[at1001] |
- |
- |
- |
- |
019 1件: 19 💬 |
17 |
[hgt-1410] |
- |
- |
- |
- |
019 1件: 19 💬 |
18 |
[otl-200] |
- |
- |
- |
- |
019 1件: 19 💬 |
19 |
[rhlaman] |
Velmanase alfa |
1件: D11024 D11024 💬 |
MAN2B1 1件: MAN2B1 💬 |
Lysosome 2件: Lysosome, Other glycan degradation |
019 1件: 19 💬 |
20 |
[shp611] |
- |
- |
- |
- |
019 1件: 19 💬 |
21 |
A (migalastat) |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
22 |
A16ab04 |
- |
- |
- |
- |
019 1件: 19 💬 |
23 |
A16ax06 |
- |
- |
- |
- |
019 1件: 19 💬 |
24 |
Aav2/8.tbg.harsb |
- |
- |
- |
- |
019 1件: 19 💬 |
25 |
Aav2cuhcln2 (3x10^12 particle units) |
- |
- |
- |
- |
019 1件: 19 💬 |
26 |
Aav9-cag-coh-sgsh |
- |
- |
- |
- |
019 1件: 19 💬 |
27 |
Aav9-glb1 |
- |
- |
- |
- |
019 1件: 19 💬 |
28 |
Aavrh.10-hmpsiiia |
- |
- |
- |
- |
019 1件: 19 💬 |
29 |
Aavrh.10cuarsa |
- |
- |
- |
- |
019 1件: 19 💬 |
30 |
Aavrh.10cucln2 |
- |
- |
- |
- |
019 1件: 19 💬 |
31 |
Aavrh.10cuhcln2 vector 2.85x10^11 genome copies |
- |
- |
- |
- |
019 1件: 19 💬 |
32 |
Aavrh.10cuhcln2 vector 9.0x10^11 genome copies |
- |
- |
- |
- |
019 1件: 19 💬 |
33 |
Abatacept |
Abatacept |
1件: D03203 D03203 💬 |
CD80 2件: CD80, CD86 💬 |
Allograft rejection 12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
011 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬 |
34 |
Abo-101 |
- |
- |
- |
- |
019 1件: 19 💬 |
35 |
Abo-102 |
- |
- |
- |
- |
019 1件: 19 💬 |
36 |
Accupro |
- |
- |
- |
- |
019 1件: 19 💬 |
37 |
Accuretic |
- |
- |
- |
- |
019 1件: 19 💬 |
38 |
Acetylcysteine |
Acetylcysteine |
1件: D00221 D00221 💬 |
- |
- |
006 16件: 6 , 13, 19, 20, 34, 49, 51, 58, 85, 94, 111, 164, 193, 233, 298, 299 💬 |
39 |
Act-434964 |
- |
- |
- |
- |
019 1件: 19 💬 |
40 |
Adalimumab |
Adalimumab |
1件: D02597 D02597 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
019 16件: 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬 |
41 |
Adalimumab injection [humira] |
Adalimumab |
1件: D02597 D02597 💬 |
TNF 1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
019 1件: 19 💬 |
42 |
Adeno-associated viral (aav) serotype 8 (aav2/8) vector with liver-specific thyroxine-binding globulin (tbg) promoter, driving the expression of the human arsb gene |
Levothyroxine |
2件: D01010 D01010, D08125 D08125 💬 |
THRA 2件: THRA, THRB 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
019 1件: 19 💬 |
43 |
Adeno-associated viral vector serotype 9 containing the human n-acetyl-alpha-glucosaminidase gene |
- |
- |
- |
- |
019 1件: 19 💬 |
44 |
Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase a cdna |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
45 |
Adeno-associated virus serotype 2/6 encoding human iduronate 2-sulfatase (hids) gene donor vector, sb-a6p-hnt donor vector |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
46 |
Adeno-associated virus serotype 2/6 encoding human iduronidase (hidua) gene donor vector, sb-a6p-hrl donor vector |
- |
- |
- |
- |
019 1件: 19 💬 |
47 |
Adeno-associated virus serotype 2/6 encoding left side-zinc finger nuclease (zfn1), sb-a6p-zleft vector |
- |
- |
- |
- |
019 1件: 19 💬 |
48 |
Adeno-associated virus serotype 2/6 encoding right side-zinc finger nuclease (zfn2), sb-a6p-zright vector |
- |
- |
- |
- |
019 1件: 19 💬 |
49 |
Administration |
- |
- |
- |
- |
019 1件: 19 💬 |
50 |
Adrabetadex |
Adrabetadex |
- |
- |
- |
019 1件: 19 💬 |
51 |
Afegostat |
Afegostat |
1件: D09576 D09576 💬 |
- |
- |
019 1件: 19 💬 |
52 |
Afegostat tartrate |
Afegostat |
1件: D09576 D09576 💬 |
- |
- |
019 1件: 19 💬 |
53 |
Agalsidase |
- |
- |
- |
- |
019 1件: 19 💬 |
54 |
Agalsidase alfa |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
55 |
Agalsidase alpha |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
56 |
Agalsidase beta |
Agalsidase beta |
1件: D03228 D03228 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
57 |
Agalsidase beta (gz419828) |
Agalsidase beta |
1件: D03228 D03228 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
58 |
Agalsidase beta (recombinant form) |
Agalsidase beta |
1件: D03228 D03228 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
59 |
Agalsidasi beta |
- |
- |
- |
- |
019 1件: 19 💬 |
60 |
Agt-181 |
- |
- |
- |
- |
019 1件: 19 💬 |
61 |
Agt-181 (hirmab-idua) |
- |
- |
- |
- |
019 1件: 19 💬 |
62 |
Agt-182 |
- |
- |
- |
- |
019 1件: 19 💬 |
63 |
Aldurazyme |
- |
- |
- |
- |
019 1件: 19 💬 |
64 |
Aldurazyme (laronidase) |
Laronidase |
1件: D04670 D04670 💬 |
IDUA 1件: IDUA 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 2件: 19, 256 💬 |
65 |
Aldurazyme (recombinant human alpha-l-iduronidase) |
- |
- |
- |
- |
019 1件: 19 💬 |
66 |
Aldurazyme*infus 1fl 5ml 500u |
- |
- |
- |
- |
019 1件: 19 💬 |
67 |
Alemtuzumab |
Alemtuzumab |
1件: D02802 D02802 💬 |
- |
- |
013 16件: 13, 15, 19, 20, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 💬 |
68 |
Alendronate |
Alendronic acid |
2件: D00939 D00939, D07119 D07119 💬 |
FDPS 1件: FDPS 💬 |
Human T-cell leukemia virus 1 infection 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
019 7件: 19, 41, 46, 50, 271, 274, 299 💬 |
69 |
Alendronate sodium |
Alendronic acid |
2件: D00939 D00939, D07119 D07119 💬 |
FDPS 1件: FDPS 💬 |
Human T-cell leukemia virus 1 infection 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis |
019 2件: 19, 299 💬 |
70 |
Alfa-manosidadas humana recombinante |
- |
- |
- |
- |
019 1件: 19 💬 |
71 |
Alpha-galactosidase a |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
72 |
Ambroxol |
Ambroxol |
1件: D07442 D07442 💬 |
- |
- |
006 2件: 6 , 19 💬 |
73 |
Anakinra |
Anakinra |
1件: D02934 D02934 💬 |
IL1R1 2件: IL1R1, IL1R2 💬 |
Amoebiasis 15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer |
002 17件: 2 , 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 84, 86, 97, 106, 107, 299 💬 |
74 |
Angiotensin |
Angiotensin II |
2件: D00150 D00150, D02014 D02014 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
017 7件: 17, 19, 46, 66, 86, 222, 224 💬 |
75 |
Arimoclomol |
Arimoclomol |
1件: D11374 D11374 💬 |
- |
- |
002 3件: 2 , 15, 19 💬 |
76 |
Arimoclomol (hard gelatine capsule) |
Arimoclomol |
3件: D00115 D00115, D06892 D06892, D11374 D11374 💬 |
- |
- |
019 1件: 19 💬 |
77 |
Arimoclomol (hpmc capsule) |
Arimoclomol |
1件: D11374 D11374 💬 |
- |
- |
019 1件: 19 💬 |
78 |
Arimoclomol citrate |
Arimoclomol |
1件: D11374 D11374 💬 |
- |
- |
015 2件: 15, 19 💬 |
79 |
Arylsulfatase a |
- |
- |
- |
- |
019 1件: 19 💬 |
80 |
At1001 |
- |
- |
- |
- |
019 1件: 19 💬 |
81 |
At1001 150 mg |
- |
- |
- |
- |
019 1件: 19 💬 |
82 |
At2101 |
- |
- |
- |
- |
019 1件: 19 💬 |
83 |
Ataluren |
Ataluren |
1件: D09323 D09323 💬 |
- |
- |
019 6件: 19, 113, 140, 246, 299, 329 💬 |
84 |
Autologous cd34+ cells transduced with a lentiviral vector containing the human sgsh gene |
- |
- |
- |
- |
019 1件: 19 💬 |
85 |
Autologous cd34+ cells transduced with a lentiviral vector encoding the arsa cdna |
- |
- |
- |
- |
019 1件: 19 💬 |
86 |
Autologous plasmablasts |
- |
- |
- |
- |
019 1件: 19 💬 |
87 |
Avr-rd-01 |
- |
- |
- |
- |
019 1件: 19 💬 |
88 |
Avr-rd-02 |
- |
- |
- |
- |
019 1件: 19 💬 |
89 |
Ax |
- |
- |
- |
- |
019 1件: 19 💬 |
90 |
Ax 250 |
- |
- |
- |
- |
019 1件: 19 💬 |
91 |
Azathioprine |
Azathioprine |
2件: D00238 D00238, D03033 D03033 💬 |
- |
- |
006 20件: 6 , 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 94, 95, 96, 97, 162 💬 |
92 |
Azathioprine (aza) |
Azathioprine |
2件: D00238 D00238, D03033 D03033 💬 |
- |
- |
013 3件: 13, 19, 97 💬 |
93 |
B (migalastat) |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
94 |
Barium |
Barium |
- |
- |
- |
019 2件: 19, 98 💬 |
95 |
Behavioral: neurocognitive testing |
- |
- |
- |
- |
019 1件: 19 💬 |
96 |
Behavioral: picc line placement |
- |
- |
- |
- |
019 1件: 19 💬 |
97 |
Beta-cyclodextrin |
Betadex |
1件: D02401 D02401 💬 |
- |
- |
019 1件: 19 💬 |
98 |
Beta-mercaptoethylamine |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
99 |
Beta-mercaptoethylamine hydrochloride & 2-aminoethanethiol hydrochloride |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
100 |
Bhp001 |
- |
- |
- |
- |
019 1件: 19 💬 |
101 |
Biological assays |
- |
- |
- |
- |
019 1件: 19 💬 |
102 |
Biopsy |
- |
- |
- |
- |
019 2件: 19, 51 💬 |
103 |
Blood sampling |
- |
- |
- |
- |
013 5件: 13, 17, 19, 51, 96 💬 |
104 |
Bm110 |
- |
- |
- |
- |
019 1件: 19 💬 |
105 |
Bmn 110 |
- |
- |
- |
- |
019 1件: 19 💬 |
106 |
Bmn 110 - every other week |
- |
- |
- |
- |
019 1件: 19 💬 |
107 |
Bmn 110 - weekly |
- |
- |
- |
- |
019 1件: 19 💬 |
108 |
Bmn 110 every other week |
- |
- |
- |
- |
019 1件: 19 💬 |
109 |
Bmn 110 weekly |
- |
- |
- |
- |
019 1件: 19 💬 |
110 |
Bmn 190 |
- |
- |
- |
- |
019 1件: 19 💬 |
111 |
Bmn 250 |
- |
- |
- |
- |
019 1件: 19 💬 |
112 |
Bmn190 recombinant human tripeptidyl peptidase-1 (rhtpp1) |
- |
- |
- |
- |
019 1件: 19 💬 |
113 |
Brineura |
- |
- |
- |
- |
019 1件: 19 💬 |
114 |
Busilvex |
- |
- |
- |
- |
019 4件: 19, 36, 60, 65 💬 |
115 |
Busilvex - 6 mg/ml - concentrato per soluzione per infusione - uso endovenoso - flaconcino - 10 ml 8 flaconcini |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
116 |
Busulfan |
Busulfan |
1件: D00248 D00248 💬 |
- |
- |
019 13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 💬 |
117 |
Busulfan, cyclophosphamide, antithymocyte globulin |
Busulfan |
3件: D00248 D00248, D00287 D00287, D07760 D07760 💬 |
- |
- |
019 2件: 19, 20 💬 |
118 |
Busulfan, cyclophosphamide, atg |
Busulfan |
3件: D00248 D00248, D00287 D00287, D07760 D07760 💬 |
- |
- |
019 1件: 19 💬 |
119 |
Busulfano |
Busulfan |
1件: D00248 D00248 💬 |
- |
- |
019 1件: 19 💬 |
120 |
C (migalastat) |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
121 |
Calcium |
Calcium |
- |
- |
- |
006 27件: 6 , 13, 19, 46, 49, 51, 53, 56, 68, 75, 79, 84, 93, 94, 95, 96, 97, 186, 214, 215, 222, 224, 235, 265, 274, 298, 299 💬 |
122 |
Calcium carbonate |
Calcium |
2件: D00932 D00932, D10802 D10802 💬 |
- |
- |
013 8件: 13, 19, 46, 53, 75, 96, 235, 299 💬 |
123 |
Cald hr-d (high-risk, regimen c) |
- |
- |
- |
- |
019 5件: 19, 20, 125, 234, 326 💬 |
124 |
Cald hr-d (high-risk, regimen d) |
- |
- |
- |
- |
019 5件: 19, 20, 125, 234, 326 💬 |
125 |
Cald sr-a (standard-risk, regimen a) |
- |
- |
- |
- |
019 5件: 19, 20, 125, 234, 326 💬 |
126 |
Cald sr-b (standard-risk, regimen b) |
- |
- |
- |
- |
019 5件: 19, 20, 125, 234, 326 💬 |
127 |
Campath |
- |
- |
- |
- |
019 12件: 19, 20, 49, 51, 60, 62, 65, 164, 234, 283, 285, 326 💬 |
128 |
Campath-1h |
- |
- |
- |
- |
019 6件: 19, 20, 60, 234, 285, 326 💬 |
129 |
Capsaicin |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
002 5件: 2 , 6 , 19, 86, 226 💬 |
130 |
Carbonate |
Carbonate ion |
- |
- |
- |
002 12件: 2 , 13, 17, 18, 19, 46, 53, 75, 96, 127, 235, 299 💬 |
131 |
Cellule cd34+ autologhe trasdotte con idua lv codificante per il cdna dell'alfa-l-iduronidasi |
- |
- |
- |
- |
019 1件: 19 💬 |
132 |
Cerdelga |
- |
- |
- |
- |
019 1件: 19 💬 |
133 |
Ceredase |
- |
- |
- |
- |
019 1件: 19 💬 |
134 |
Ceredase™ |
- |
- |
- |
- |
019 1件: 19 💬 |
135 |
Cerezyme |
- |
- |
- |
- |
019 1件: 19 💬 |
136 |
Cerezyme (imiglucerase for injection) |
Imiglucerase |
2件: D02810 D02810, D03020 D03020 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
137 |
Cerezyme® |
- |
- |
- |
- |
019 1件: 19 💬 |
138 |
Cerezyme® / imiglucerase |
Imiglucerase |
2件: D02810 D02810, D03020 D03020 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
139 |
Cerliponase alfa |
Cerliponase alfa |
1件: D10813 D10813 💬 |
TPP1 1件: TPP1 💬 |
Lysosome 1件: Lysosome |
019 1件: 19 💬 |
140 |
Chemically modified recombinant human sulfamidase |
- |
- |
- |
- |
019 1件: 19 💬 |
141 |
Cholecalciferol |
Cholecalciferol |
1件: D00188 D00188 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
013 9件: 13, 19, 34, 46, 49, 96, 97, 298, 299 💬 |
142 |
Cholesterol |
Cholesterol |
1件: D00040 D00040 💬 |
- |
- |
019 6件: 19, 90, 160, 259, 261, 310 💬 |
143 |
Clofarabine |
Clofarabine |
1件: D03546 D03546 💬 |
POLA1 3件: POLA1, POLA2, RRM1 💬 |
DNA replication 6件: DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 💬 |
144 |
Coversyl |
- |
- |
- |
- |
019 2件: 19, 167 💬 |
145 |
Coversyl plus |
- |
- |
- |
- |
019 1件: 19 💬 |
146 |
Cryopreserved autologous cd34+ cells transduced with a lentiviral vector containing human sgsh gene |
- |
- |
- |
- |
019 1件: 19 💬 |
147 |
Csa |
- |
- |
- |
- |
019 8件: 19, 49, 50, 53, 60, 63, 222, 228 💬 |
148 |
Cyclophosphamide |
Cyclophosphamide |
2件: D00287 D00287, D07760 D07760 💬 |
- |
- |
011 44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 💬 |
149 |
Cyclosporine |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 35件: 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 63, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 💬 |
150 |
Cyclosporine a |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
019 10件: 19, 20, 36, 49, 50, 53, 58, 60, 234, 283 💬 |
151 |
Cyclosporine a (csa) |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
019 2件: 19, 60 💬 |
152 |
Cystadane anhydrous |
- |
- |
- |
- |
019 1件: 19 💬 |
153 |
Cystadrops |
- |
- |
- |
- |
019 1件: 19 💬 |
154 |
Cystadrops 0.55% eye drops, solution |
- |
- |
- |
- |
019 1件: 19 💬 |
155 |
Cystagon |
- |
- |
- |
- |
008 3件: 8 , 19, 299 💬 |
156 |
Cystagon 150mg |
- |
- |
- |
- |
019 1件: 19 💬 |
157 |
Cystagon 50mg |
- |
- |
- |
- |
019 1件: 19 💬 |
158 |
Cystagon® |
- |
- |
- |
- |
019 1件: 19 💬 |
159 |
Cystagon® (cysteamine bitartrate) |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
160 |
Cysteamine |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
008 4件: 8 , 19, 21, 299 💬 |
161 |
Cysteamine (mercaptamine) viscous solution |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
162 |
Cysteamine bitartrate |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
008 4件: 8 , 19, 21, 299 💬 |
163 |
Cysteamine bitartrate (inn: mercaptamine bitartrate |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
164 |
Cysteamine bitartrate (inn: mercaptamine bitartrate ) |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
165 |
Cysteamine bitartrate (inn: mercaptamine bitartrate) |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
166 |
Cysteamine bitartrate delayed-release capsules |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
167 |
Cysteamine bitartrate delayed-release capsules (rp103) |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
168 |
Cysteamine hydrochloride |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
169 |
Cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 11件: 6 , 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 💬 |
170 |
D (migalastat) |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
171 |
Device: administration kit |
- |
- |
- |
- |
019 1件: 19 💬 |
172 |
Device: cyclosporine a |
Cyclosporine |
1件: D00184 D00184 💬 |
PPP3CA 5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease 32件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
019 2件: 19, 20 💬 |
173 |
Device: intraventricular access device |
- |
- |
- |
- |
019 1件: 19 💬 |
174 |
Device: mechanical stimulation with von frey filaments |
- |
- |
- |
- |
019 1件: 19 💬 |
175 |
Device: mri with contrast agent injection |
- |
- |
- |
- |
019 1件: 19 💬 |
176 |
Device: mri without contrast agent injection |
- |
- |
- |
- |
019 1件: 19 💬 |
177 |
Device: osome |
- |
- |
- |
- |
019 1件: 19 💬 |
178 |
Device: temperature sensitivity measurement with advanced thermal stimulation |
- |
- |
- |
- |
019 1件: 19 💬 |
179 |
Diagnostic test: audiology assessmentwith abr |
- |
- |
- |
- |
019 1件: 19 💬 |
180 |
Diagnostic test: bone density scan (dexa |
- |
- |
- |
- |
019 1件: 19 💬 |
181 |
Diagnostic test: echocardiogram |
- |
- |
- |
- |
019 1件: 19 💬 |
182 |
Diagnostic test: echocardiography at m24 |
- |
- |
- |
- |
019 1件: 19 💬 |
183 |
Diagnostic test: echocardiography at t0 |
- |
- |
- |
- |
019 1件: 19 💬 |
184 |
Diagnostic test: electrocardiogram (ekg) |
- |
- |
- |
- |
019 1件: 19 💬 |
185 |
Diagnostic test: exercise test |
- |
- |
- |
- |
019 1件: 19 💬 |
186 |
Diagnostic test: laboratory tests |
- |
- |
- |
- |
019 1件: 19 💬 |
187 |
Dnl310 |
- |
- |
- |
- |
019 1件: 19 💬 |
188 |
Dnl310 drug substance |
- |
- |
- |
- |
019 1件: 19 💬 |
189 |
Dried blood spot (dbs) sampling |
- |
- |
- |
- |
019 1件: 19 💬 |
190 |
Drx005b |
- |
- |
- |
- |
019 1件: 19 💬 |
191 |
Duoc-01 |
- |
- |
- |
- |
019 2件: 19, 20 💬 |
192 |
E (migalastat) |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
193 |
Elaprase |
- |
- |
- |
- |
019 1件: 19 💬 |
194 |
Elaprase 2mg/ml |
- |
- |
- |
- |
019 1件: 19 💬 |
195 |
Elaprase for intravenous (iv) infusion |
- |
- |
- |
- |
019 1件: 19 💬 |
196 |
Elaprase_0.5mg/kg |
- |
- |
- |
- |
019 1件: 19 💬 |
197 |
Elelyso |
- |
- |
- |
- |
019 1件: 19 💬 |
198 |
Elelyso 60 units/kg |
- |
- |
- |
- |
019 1件: 19 💬 |
199 |
Eliglustat |
Eliglustat |
1件: D09893 D09893 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
200 |
Eliglustat gz385660 |
Eliglustat |
1件: D09893 D09893 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
201 |
Eliglustat tartrate |
Eliglustat |
1件: D09893 D09893 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
202 |
Elosulfase alfa |
Elosulfase alfa |
1件: D10333 D10333 💬 |
GALNS 1件: GALNS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
203 |
Elosulfase alfa 1 mg/ml intravenous solution [vimizim] |
Elosulfase alfa |
1件: D10333 D10333 💬 |
GALNS 1件: GALNS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
204 |
Elx-02 |
ELX-02 |
- |
- |
- |
019 2件: 19, 299 💬 |
205 |
Enalapril |
Enalapril |
2件: D00621 D00621, D07892 D07892 💬 |
ACE 1件: ACE 💬 |
Chagas disease 6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
019 7件: 19, 46, 66, 113, 210, 222, 223 💬 |
206 |
Enalapril and other angiotensin converting enzyme inhibitors |
Angiotensin II |
4件: D00150 D00150, D00621 D00621, D02014 D02014, D07892 D07892 💬 |
ACE 3件: ACE, AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
019 1件: 19 💬 |
207 |
Enriched hematopoetic stem cell infusion |
- |
- |
- |
- |
013 3件: 13, 19, 284 💬 |
208 |
Enzyme replacement |
- |
- |
- |
- |
019 1件: 19 💬 |
209 |
Enzyme replacement therapy |
- |
- |
- |
- |
019 1件: 19 💬 |
210 |
Enzyme replacement therapy (agalsidase alpha (replagal®)) |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
211 |
Enzyme replacement therapy (ert) |
- |
- |
- |
- |
019 1件: 19 💬 |
212 |
Ert |
- |
- |
- |
- |
019 1件: 19 💬 |
213 |
Fabrazyme |
- |
- |
- |
- |
019 1件: 19 💬 |
214 |
Fabrazyme (agalsidase beta) |
Agalsidase beta |
1件: D03228 D03228 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
215 |
Fabrazyme - 35 mg polvere per concentrato per soluzione per infusione endovenosa 1 flaconcino |
- |
- |
- |
- |
019 1件: 19 💬 |
216 |
Fabrazyme 35 mg |
- |
- |
- |
- |
019 1件: 19 💬 |
217 |
Fabrazyme 5 mg |
- |
- |
- |
- |
019 1件: 19 💬 |
218 |
Flt190 |
- |
- |
- |
- |
019 1件: 19 💬 |
219 |
Fludarabina |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 2件: 19, 65 💬 |
220 |
Fludarabina accord - 25 mg/ml concentrato per soluzione iniettabile o per infusione 5 flaconcini in vetro da 2 ml |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 1件: 19 💬 |
221 |
Fludarabina fosfato |
Fludarabine |
2件: D01907 D01907, D07966 D07966 💬 |
RRM1 1件: RRM1 💬 |
Drug metabolism - other enzymes 5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
019 1件: 19 💬 |
222 |
Fluorescein |
Fluorescein |
2件: D01261 D01261, D02024 D02024 💬 |
- |
- |
019 2件: 19, 97 💬 |
223 |
Ga-gcb |
Velaglucerase alfa |
1件: D09029 D09029 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
224 |
Ga-gcb (velaglucerase alfa) |
Velaglucerase alfa |
1件: D09029 D09029 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
225 |
Gabapentin |
Gabapentin |
1件: D00332 D00332 💬 |
CACNA2D1 5件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 |
Adrenergic signaling in cardiomyocytes 9件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle |
006 5件: 6 , 13, 19, 70, 298 💬 |
226 |
Galafold |
- |
- |
- |
- |
019 1件: 19 💬 |
227 |
Galsulfase |
Galsulfase |
1件: D06565 D06565 💬 |
ARSB 1件: ARSB 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
228 |
Gc1111_0.5mg/kg |
- |
- |
- |
- |
019 1件: 19 💬 |
229 |
Gc1111_1.0mg/kg |
- |
- |
- |
- |
019 1件: 19 💬 |
230 |
Gc1119 |
- |
- |
- |
- |
019 1件: 19 💬 |
231 |
Gelatine |
Gelatin |
2件: D00115 D00115, D06892 D06892 💬 |
- |
- |
019 1件: 19 💬 |
232 |
Gene activated human glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
233 |
Gene activated human glucocerebrosidase, velaglucerase alfa |
Velaglucerase alfa |
1件: D09029 D09029 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
234 |
Gene-activated human glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
235 |
Gene-activated human glucocerebrosidase 200u/vial |
- |
- |
- |
- |
019 1件: 19 💬 |
236 |
Gene-activated human glucocerebrosidase 400u/vial |
- |
- |
- |
- |
019 1件: 19 💬 |
237 |
Genetic: gla gene |
- |
- |
- |
- |
019 1件: 19 💬 |
238 |
Genetic: lys-gm101 |
- |
- |
- |
- |
019 1件: 19 💬 |
239 |
Genistein |
Genistein |
1件: D11680 D11680 💬 |
- |
- |
019 2件: 19, 299 💬 |
240 |
Genistein aglycone |
Genistein |
1件: D11680 D11680 💬 |
- |
- |
019 1件: 19 💬 |
241 |
Genz-112638 |
- |
- |
- |
- |
019 1件: 19 💬 |
242 |
Genz-682452 |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
006 3件: 6 , 19, 67 💬 |
243 |
Genz-682452-aa |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
244 |
Genz-682452-au |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
006 3件: 6 , 19, 67 💬 |
245 |
Gla |
- |
- |
- |
- |
013 2件: 13, 19 💬 |
246 |
Glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
247 |
Glucocerebrosidase umano gene-attivato |
- |
- |
- |
- |
019 1件: 19 💬 |
248 |
Gnr-055 |
- |
- |
- |
- |
019 1件: 19 💬 |
249 |
Gr181413 |
- |
- |
- |
- |
019 1件: 19 💬 |
250 |
Gr181413a |
- |
- |
- |
- |
019 1件: 19 💬 |
251 |
Gr181413a/at1001 capsule |
- |
- |
- |
- |
019 1件: 19 💬 |
252 |
Gr181413a/at1001 solution |
- |
- |
- |
- |
019 1件: 19 💬 |
253 |
Growth hormone |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
002 12件: 2 , 13, 19, 46, 78, 96, 187, 191, 193, 195, 265, 299 💬 |
254 |
Gsk2788723 |
- |
- |
- |
- |
019 1件: 19 💬 |
255 |
Gz/sar402671 |
- |
- |
- |
- |
006 2件: 6 , 19 💬 |
256 |
Gz385660 |
- |
- |
- |
- |
019 1件: 19 💬 |
257 |
Gz402665 |
- |
- |
- |
- |
019 1件: 19 💬 |
258 |
Gz402671 |
- |
- |
- |
- |
019 2件: 19, 67 💬 |
259 |
Gz402671 / sar402671 |
- |
- |
- |
- |
019 1件: 19 💬 |
260 |
Hematopoetic stem cell transplantation |
- |
- |
- |
- |
019 5件: 19, 65, 120, 160, 326 💬 |
261 |
Hematopoietic stem cell infusion |
- |
- |
- |
- |
019 2件: 19, 20 💬 |
262 |
Hematopoietic stem cell transplantation |
- |
- |
- |
- |
011 12件: 11, 13, 14, 19, 20, 35, 46, 49, 51, 96, 234, 285 💬 |
263 |
Heparán n sulfatasa humana recombinante |
- |
- |
- |
- |
019 1件: 19 💬 |
264 |
Heparán n sulfatasa humana recombinante (rhhns) |
- |
- |
- |
- |
019 1件: 19 💬 |
265 |
Hgt-1110 |
- |
- |
- |
- |
019 1件: 19 💬 |
266 |
Hgt-1111 |
- |
- |
- |
- |
019 1件: 19 💬 |
267 |
Hgt-1410 |
- |
- |
- |
- |
019 1件: 19 💬 |
268 |
Hgt-2310 |
- |
- |
- |
- |
019 1件: 19 💬 |
269 |
Hids donor |
- |
- |
- |
- |
019 1件: 19 💬 |
270 |
Hucns-sc |
- |
- |
- |
- |
019 1件: 19 💬 |
271 |
Human glucocerebrosidase (prgcd) |
Taliglucerase alfa |
1件: D09675 D09675 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
272 |
Human placental derived stem cell |
- |
- |
- |
- |
019 4件: 19, 20, 60, 284 💬 |
273 |
Hunterase |
Idursulfase beta |
1件: D11025 D11025 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
274 |
Hydroxypropyl-beta-cyclodextrin |
Betadex |
1件: D02401 D02401 💬 |
- |
- |
019 1件: 19 💬 |
275 |
Hydroxypropyl-ß-cyclodextrin |
- |
- |
- |
- |
019 1件: 19 💬 |
276 |
Hydroxyurea |
Hydroxyurea |
1件: D00341 D00341 💬 |
RRM2 1件: RRM2 💬 |
Drug metabolism - other enzymes 6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway |
003 8件: 3 , 13, 19, 20, 65, 85, 86, 284 💬 |
277 |
I2s |
- |
- |
- |
- |
019 1件: 19 💬 |
278 |
I2s-it |
- |
- |
- |
- |
019 1件: 19 💬 |
279 |
Ib1001 |
- |
- |
- |
- |
019 1件: 19 💬 |
280 |
Iduronate 2-sulfatase |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
281 |
Iduronate-2-sulfatase enzyme replacement therapy |
- |
- |
- |
- |
019 1件: 19 💬 |
282 |
Iduronate-2-sulfatase fused to a fc polypeptide that binds to the human transferrin receptor |
- |
- |
- |
- |
019 1件: 19 💬 |
283 |
Idursulfasa |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
284 |
Idursulfase |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
285 |
Idursulfase (i2s) |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
286 |
Idursulfase (i2s)-it |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
287 |
Idursulfase beta |
Idursulfase |
2件: D04499 D04499, D11025 D11025 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
288 |
Idursulfase it (1 mg) |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
289 |
Idursulfase it (10 mg) |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
290 |
Idursulfase it (30 mg) |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
291 |
Idursulfase(12s)-it |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
292 |
Idursulfase(i2s)-it |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
293 |
Idursulfase-it |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
294 |
Igf2 |
- |
- |
- |
- |
019 1件: 19 💬 |
295 |
Imd |
- |
- |
- |
- |
019 5件: 19, 20, 125, 234, 326 💬 |
296 |
Imd preparative regimen |
- |
- |
- |
- |
019 5件: 19, 20, 125, 234, 326 💬 |
297 |
Imiglucerasa |
Imiglucerase |
2件: D02810 D02810, D03020 D03020 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
298 |
Imiglucerase |
Imiglucerase |
2件: D02810 D02810, D03020 D03020 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
299 |
Imiglucerase gz437843 |
Imiglucerase |
2件: D02810 D02810, D03020 D03020 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
300 |
Imiglucerasi |
- |
- |
- |
- |
019 1件: 19 💬 |
301 |
Imiglucérase (drug) pharmacokinetics |
- |
- |
- |
- |
019 1件: 19 💬 |
302 |
Inactive reminder capsules |
- |
- |
- |
- |
019 1件: 19 💬 |
303 |
Inactive reminder product |
- |
- |
- |
- |
019 1件: 19 💬 |
304 |
Inn not available |
- |
- |
- |
- |
019 2件: 19, 46 💬 |
305 |
Innozide |
- |
- |
- |
- |
019 1件: 19 💬 |
306 |
Intrathecal recombinant human alpha iduronidase |
- |
- |
- |
- |
019 1件: 19 💬 |
307 |
Iohexol |
Iohexol |
1件: D01817 D01817 💬 |
- |
- |
019 2件: 19, 67 💬 |
308 |
Irt laronidase |
Laronidase |
1件: D04670 D04670 💬 |
IDUA 1件: IDUA 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
309 |
Isofagamine tartrate |
- |
- |
- |
- |
019 1件: 19 💬 |
310 |
Isu302 |
- |
- |
- |
- |
019 1件: 19 💬 |
311 |
Iv migalastat hcl |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
312 |
Iva 336 |
- |
- |
- |
- |
019 1件: 19 💬 |
313 |
Jr-141 |
- |
- |
- |
- |
019 1件: 19 💬 |
314 |
Jr-141 or idursulfase |
Idursulfase |
1件: D04499 D04499 💬 |
IDS 1件: IDS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
315 |
Jr-171 |
- |
- |
- |
- |
019 1件: 19 💬 |
316 |
Kanuma |
- |
- |
- |
- |
019 1件: 19 💬 |
317 |
Lamazym |
Velmanase alfa |
1件: D11024 D11024 💬 |
MAN2B1 1件: MAN2B1 💬 |
Lysosome 2件: Lysosome, Other glycan degradation |
019 1件: 19 💬 |
318 |
Laronidase |
Laronidase |
1件: D04670 D04670 💬 |
IDUA 1件: IDUA 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 2件: 19, 256 💬 |
319 |
Laronidase ert |
Laronidase |
1件: D04670 D04670 💬 |
IDUA 1件: IDUA 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
320 |
Ledipasvir |
Ledipasvir |
1件: D10442 D10442 💬 |
- |
- |
019 1件: 19 💬 |
321 |
Ledipasvir/sofosbuvir |
Ledipasvir |
2件: D10366 D10366, D10442 D10442 💬 |
- |
- |
019 1件: 19 💬 |
322 |
Lenograstim |
Lenograstim |
1件: D03247 D03247 💬 |
CSF3R 1件: CSF3R 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer |
002 7件: 2 , 13, 16, 18, 19, 57, 65 💬 |
323 |
Lentivirus alpha-gal a transduced stem cells |
- |
- |
- |
- |
019 1件: 19 💬 |
324 |
Lentivirus-mediated delivery of arsa to the cns. |
- |
- |
- |
- |
019 1件: 19 💬 |
325 |
Leucine |
Leucine |
1件: D00030 D00030 💬 |
- |
- |
005 10件: 5 , 6 , 7 , 19, 96, 97, 127, 283, 284, 299 💬 |
326 |
Leucovorin |
Leucovorin |
3件: D01211 D01211, D07986 D07986, D07987 D07987 💬 |
- |
- |
019 2件: 19, 46 💬 |
327 |
Lipasa ácida lisosómica, esterasa, colesterol (gen humano lipa), lipasa ácida lisosómica (gen humano lipa) |
- |
- |
- |
- |
019 1件: 19 💬 |
328 |
Lisinopril |
Lisinopril |
2件: D00362 D00362, D08131 D08131 💬 |
ACE 1件: ACE 💬 |
Chagas disease 6件: Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system |
019 7件: 19, 46, 49, 66, 67, 113, 222 💬 |
329 |
Lithium carbonate |
Carbonate ion |
1件: D00801 D00801 💬 |
- |
- |
002 6件: 2 , 13, 17, 18, 19, 127 💬 |
330 |
Lopace |
- |
- |
- |
- |
019 1件: 19 💬 |
331 |
Losartan |
Losartan |
2件: D00357 D00357, D08146 D08146 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
017 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬 |
332 |
Losartan and other angiotensin receptor blockers |
Angiotensin II |
4件: D00150 D00150, D00357 D00357, D02014 D02014, D08146 D08146 💬 |
AGTR1 2件: AGTR1, AGTR2 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
019 1件: 19 💬 |
333 |
Lucerastat |
Lucerastat |
1件: D11439 D11439 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
334 |
Lys |
- |
- |
- |
- |
019 1件: 19 💬 |
335 |
Lys-saf302 |
- |
- |
- |
- |
019 1件: 19 💬 |
336 |
Lysodase |
- |
- |
- |
- |
019 1件: 19 💬 |
337 |
Lysosomal acid lipase, esterase cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa) |
Cholesterol |
1件: D00040 D00040 💬 |
- |
- |
019 1件: 19 💬 |
338 |
Lysosomal acid lipase, esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa) |
Cholesterol |
1件: D00040 D00040 💬 |
- |
- |
019 1件: 19 💬 |
339 |
Mabthera |
- |
- |
- |
- |
011 22件: 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 💬 |
340 |
Mabthera - 2 fiale 100 mg 10 ml |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
341 |
Medication to suppress the immune system |
- |
- |
- |
- |
019 1件: 19 💬 |
342 |
Melphalan |
Melphalan |
1件: D00369 D00369 💬 |
- |
- |
011 15件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 💬 |
343 |
Mepsevii |
- |
- |
- |
- |
019 1件: 19 💬 |
344 |
Mercaptamina |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
345 |
Mercaptamine |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
346 |
Mercaptamine bitartrate |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
347 |
Mercaptamine hydrochloride |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
348 |
Mercaptamine, mercamine, 2-aminoethanethiol |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
349 |
Metazym |
- |
- |
- |
- |
019 1件: 19 💬 |
350 |
Methotrexate |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
011 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬 |
351 |
Methylprednisolone |
Methylprednisolone |
6件: D00407 D00407, D00751 D00751, D00979 D00979, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 44件: 2 , 6 , 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬 |
352 |
Migalastat |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
353 |
Migalastat hcl |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
354 |
Migalastat hcl 150 mg |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
355 |
Migalastat hydrochloride |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
356 |
Migalastat hydrocloride |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
357 |
Miglustat |
Miglustat |
1件: D05032 D05032 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 3件: 19, 256, 299 💬 |
358 |
Miglustat (zavesca) |
Miglustat |
1件: D05032 D05032 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
359 |
Monitor |
Methamidophos |
- |
- |
- |
002 18件: 2 , 11, 13, 19, 46, 49, 58, 65, 70, 85, 86, 98, 113, 118, 129, 298, 299, 300 💬 |
360 |
Moss-agal (recombinant human alpha-galactosidase a produced in moss) |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
361 |
Mozobil |
- |
- |
- |
- |
019 3件: 19, 65, 285 💬 |
362 |
Mozobil - 20 mg/ml - soluzione iniettabile - uso sottocutaneo - f |
- |
- |
- |
- |
019 1件: 19 💬 |
363 |
Mycophenolate |
Mycophenolic acid |
1件: D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 34件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
364 |
Mycophenolate mofetil |
Mycophenolate mofetil |
4件: D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 2件: IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes 3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 32件: 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 |
365 |
Mycophenylate mofetil |
- |
- |
- |
- |
019 2件: 19, 20 💬 |
366 |
Myelostim - 34 1 flaconcino liofilizzato 33.6 miu + siringa preriempita solvente 1 ml |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
367 |
N acetyl cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 2件: 6 , 19 💬 |
368 |
N acetyl l leucine |
Leucine |
1件: D00030 D00030 💬 |
- |
- |
019 1件: 19 💬 |
369 |
N-acetyl cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
013 7件: 13, 19, 34, 85, 88, 296, 310 💬 |
370 |
N-acetyl-l-leucine |
Leucine |
1件: D00030 D00030 💬 |
- |
- |
019 1件: 19 💬 |
371 |
N-acetylcysteine |
Acetylcysteine |
1件: D00221 D00221 💬 |
- |
- |
006 10件: 6 , 13, 19, 20, 49, 58, 85, 111, 164, 299 💬 |
372 |
N-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
019 1件: 19 💬 |
373 |
N-acetylgalactosamine-6-sulfatase |
Elosulfase alfa |
1件: D10333 D10333 💬 |
GALNS 1件: GALNS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
374 |
Naglazyme |
- |
- |
- |
- |
019 1件: 19 💬 |
375 |
Naglazyme (galsulfase) |
Galsulfase |
1件: D06565 D06565 💬 |
ARSB 1件: ARSB 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
376 |
Naglazyme® |
- |
- |
- |
- |
019 1件: 19 💬 |
377 |
Non applicable |
- |
- |
- |
- |
010 2件: 10, 19 💬 |
378 |
Odiparcil |
Odiparcil |
- |
- |
- |
019 1件: 19 💬 |
379 |
Ogt 918 |
- |
- |
- |
- |
019 2件: 19, 299 💬 |
380 |
Ogt918 |
- |
- |
- |
- |
019 1件: 19 💬 |
381 |
Ogt923 |
- |
- |
- |
- |
019 1件: 19 💬 |
382 |
Olenasufligene relduparvovec |
Olenasufligene relduparvovec |
- |
- |
- |
019 1件: 19 💬 |
383 |
Olipudase alfa |
Olipudase alfa |
1件: D10820 D10820 💬 |
SMPD1 1件: SMPD1 💬 |
Lysosome 5件: Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway |
019 1件: 19 💬 |
384 |
Olipudase alfa (rhasm) |
Olipudase alfa |
1件: D10820 D10820 💬 |
SMPD1 1件: SMPD1 💬 |
Lysosome 5件: Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway |
019 1件: 19 💬 |
385 |
Omnipaque |
- |
- |
- |
- |
019 1件: 19 💬 |
386 |
Oral migalastat hcl |
Migalastat |
1件: D10359 D10359 💬 |
- |
- |
019 1件: 19 💬 |
387 |
Osteopetrosis haploidentical only preparative regimen |
- |
- |
- |
- |
019 5件: 19, 20, 125, 234, 326 💬 |
388 |
Osteopetrosis only preparative regimen |
- |
- |
- |
- |
019 5件: 19, 20, 125, 234, 326 💬 |
389 |
Other: brief pain inventory questionnaire |
- |
- |
- |
- |
019 1件: 19 💬 |
390 |
Other: challenge agent: capsaicin |
Capsaicin |
1件: D00250 D00250 💬 |
TRPV1 1件: TRPV1 💬 |
Inflammatory mediator regulation of TRP channels 2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
019 1件: 19 💬 |
391 |
Other: control |
- |
- |
- |
- |
006 8件: 6 , 19, 70, 75, 85, 97, 162, 193 💬 |
392 |
Other: cysteamine bitartrate |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
393 |
Other: electroencephalogram (eeg) awake andextended overnight |
- |
- |
- |
- |
019 1件: 19 💬 |
394 |
Other: fluorescein angiography |
Fluorescein |
2件: D01261 D01261, D02024 D02024 💬 |
- |
- |
019 1件: 19 💬 |
395 |
Other: general and neurological examination |
- |
- |
- |
- |
019 1件: 19 💬 |
396 |
Other: ketogenic diet |
- |
- |
- |
- |
019 1件: 19 💬 |
397 |
Other: neurology exam |
- |
- |
- |
- |
019 1件: 19 💬 |
398 |
Other: no it treatment |
- |
- |
- |
- |
019 1件: 19 💬 |
399 |
Other: palliative care |
- |
- |
- |
- |
019 5件: 19, 65, 120, 160, 326 💬 |
400 |
Other: potable water |
Water |
1件: D00001 D00001 💬 |
- |
- |
019 1件: 19 💬 |
401 |
Other: quality of life questionnaire |
- |
- |
- |
- |
019 1件: 19 💬 |
402 |
Other: sham |
- |
- |
- |
- |
019 2件: 19, 301 💬 |
403 |
Other: vital signs |
- |
- |
- |
- |
019 1件: 19 💬 |
404 |
Otl-200 dispersion for infusion |
- |
- |
- |
- |
019 1件: 19 💬 |
405 |
Oxygen |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
006 18件: 6 , 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 294, 299, 330 💬 |
406 |
Paricalcitol |
Paricalcitol |
1件: D00930 D00930 💬 |
VDR 1件: VDR 💬 |
Endocrine and other factor-regulated calcium reabsorption 4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
019 3件: 19, 66, 218 💬 |
407 |
Pegunigalsidase alfa |
Pegunigalsidase alfa |
1件: D11685 D11685 💬 |
- |
- |
019 1件: 19 💬 |
408 |
Pegunigalsidase alpha |
- |
- |
- |
- |
019 1件: 19 💬 |
409 |
Pending |
- |
- |
- |
- |
013 6件: 13, 19, 96, 97, 113, 302 💬 |
410 |
Pentosan polysulfat sp 54® injection solution |
- |
- |
- |
- |
019 1件: 19 💬 |
411 |
Pentosan polysulfate |
Pentosan polysulfate |
1件: D05428 D05428 💬 |
- |
- |
019 3件: 19, 26, 226 💬 |
412 |
Pentosan polysulfate sodium |
Pentosan polysulfate |
1件: D05428 D05428 💬 |
- |
- |
019 1件: 19 💬 |
413 |
Pentosan polysulphate sp54 |
- |
- |
- |
- |
019 1件: 19 💬 |
414 |
Pentosan polysulphate sp54® |
- |
- |
- |
- |
019 1件: 19 💬 |
415 |
Perdix |
- |
- |
- |
- |
019 1件: 19 💬 |
416 |
Plant cell expressed recombinant glucocerebrosidase (prgcd) |
Taliglucerase alfa |
1件: D09675 D09675 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
417 |
Plant cell recombinant glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
418 |
Plx-200 |
- |
- |
- |
- |
019 1件: 19 💬 |
419 |
Pr001 |
- |
- |
- |
- |
019 1件: 19 💬 |
420 |
Prednisone |
Prednisone |
1件: D00473 D00473 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
002 47件: 2 , 6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬 |
421 |
Prevenar13 |
- |
- |
- |
- |
019 2件: 19, 265 💬 |
422 |
Prgcd |
Taliglucerase alfa |
1件: D09675 D09675 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
423 |
Procedure: 12 lead electrocardiogram |
- |
- |
- |
- |
019 1件: 19 💬 |
424 |
Procedure: 2-hour holter monitor |
Methamidophos |
- |
- |
- |
019 1件: 19 💬 |
425 |
Procedure: allogeneic stem cell transplantation |
- |
- |
- |
- |
019 3件: 19, 20, 62 💬 |
426 |
Procedure: blood draw |
- |
- |
- |
- |
006 5件: 6 , 19, 65, 231, 299 💬 |
427 |
Procedure: brain mri/mrs/fmri |
- |
- |
- |
- |
019 1件: 19 💬 |
428 |
Procedure: contrast sensitivity measurement |
- |
- |
- |
- |
019 1件: 19 💬 |
429 |
Procedure: dexa scan |
- |
- |
- |
- |
019 3件: 19, 46, 96 💬 |
430 |
Procedure: echocardiogram |
- |
- |
- |
- |
019 1件: 19 💬 |
431 |
Procedure: lumbar puncture |
- |
- |
- |
- |
006 5件: 6 , 13, 19, 96, 97 💬 |
432 |
Procedure: magnetic resonance imaging |
- |
- |
- |
- |
019 1件: 19 💬 |
433 |
Procedure: ophthalmology exam |
- |
- |
- |
- |
019 1件: 19 💬 |
434 |
Procedure: oxygen flow at the optic nerve head measurement |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
019 1件: 19 💬 |
435 |
Procedure: quantitative chemical shift imaging (qcsi) |
- |
- |
- |
- |
019 1件: 19 💬 |
436 |
Procedure: skeletal survey |
- |
- |
- |
- |
019 1件: 19 💬 |
437 |
Procedure: skin biopsy |
- |
- |
- |
- |
019 2件: 19, 84 💬 |
438 |
Procedure: slit lamp assessment and intra-ocular pressure measurement |
- |
- |
- |
- |
019 1件: 19 💬 |
439 |
Procedure: speech and modified barium swallow study |
Barium |
- |
- |
- |
019 1件: 19 💬 |
440 |
Procedure: stem cell transplant |
- |
- |
- |
- |
019 5件: 19, 20, 65, 164, 284 💬 |
441 |
Procedure: stem cell transplantation |
- |
- |
- |
- |
019 6件: 19, 51, 60, 62, 65, 326 💬 |
442 |
Procedure: surgery to implant human cns stem cells (hucns-sc) |
- |
- |
- |
- |
019 1件: 19 💬 |
443 |
Procedure: total body irradiation |
- |
- |
- |
- |
019 6件: 19, 20, 51, 60, 65, 285 💬 |
444 |
Procedure: urine collection |
- |
- |
- |
- |
019 1件: 19 💬 |
445 |
Procedure: visual field testing |
- |
- |
- |
- |
019 1件: 19 💬 |
446 |
Procedure: whole body protein turnover |
- |
- |
- |
- |
019 4件: 19, 46, 96, 299 💬 |
447 |
Procysbi |
- |
- |
- |
- |
019 1件: 19 💬 |
448 |
Prx-102 |
- |
- |
- |
- |
019 1件: 19 💬 |
449 |
Prx-102 (pegunigalsidase alfa) |
Pegunigalsidase alfa |
1件: D11685 D11685 💬 |
- |
- |
019 1件: 19 💬 |
450 |
Prx-112 |
- |
- |
- |
- |
019 1件: 19 💬 |
451 |
Prx102 |
- |
- |
- |
- |
019 1件: 19 💬 |
452 |
Ptc124 |
- |
- |
- |
- |
019 4件: 19, 113, 246, 299 💬 |
453 |
Pyrimethamine |
Pyrimethamine |
1件: D00488 D00488 💬 |
- |
- |
002 4件: 2 , 4 , 19, 65 💬 |
454 |
Raav 2/6 hids donor |
- |
- |
- |
- |
019 1件: 19 💬 |
455 |
Raav2/5-hnaglu |
- |
- |
- |
- |
019 1件: 19 💬 |
456 |
Raav2/6 left zfn vector |
- |
- |
- |
- |
019 1件: 19 💬 |
457 |
Raav2/6 right zfn vector |
- |
- |
- |
- |
019 1件: 19 💬 |
458 |
Raav9.cmv.hnaglu |
- |
- |
- |
- |
019 1件: 19 💬 |
459 |
Radiation: total body irradiation with marrow boosting |
- |
- |
- |
- |
019 2件: 19, 234 💬 |
460 |
Rebisufligene etisparvovec |
- |
- |
- |
- |
019 1件: 19 💬 |
461 |
Recombinant adeno-associated virus 2/6 vector encoding the cdna for human alpha galactosidase a |
- |
- |
- |
- |
019 1件: 19 💬 |
462 |
Recombinant alpha-galactosidase a |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
463 |
Recombinant human acid sphingomyelinase (rhasm) |
- |
- |
- |
- |
019 1件: 19 💬 |
464 |
Recombinant human alpha-galactosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
465 |
Recombinant human alpha-galactosidase abbreviated as r-h-alpha-gal |
- |
- |
- |
- |
019 1件: 19 💬 |
466 |
Recombinant human alpha-mannosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
467 |
Recombinant human alpha-n-acetylglucosaminidase (rhnaglu) |
- |
- |
- |
- |
019 1件: 19 💬 |
468 |
Recombinant human arylsulfatase a |
- |
- |
- |
- |
019 1件: 19 💬 |
469 |
Recombinant human arylsulfatase a (rhasa) |
- |
- |
- |
- |
019 1件: 19 💬 |
470 |
Recombinant human arylsulfatase a (rhasa, |
- |
- |
- |
- |
019 1件: 19 💬 |
471 |
Recombinant human arysulfatase b, recombinant human n-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
019 1件: 19 💬 |
472 |
Recombinant human beta glucuronidase |
- |
- |
- |
- |
019 1件: 19 💬 |
473 |
Recombinant human beta-glucuronidase |
Vestronidase alfa |
1件: D11004 D11004 💬 |
GUSB 1件: GUSB 💬 |
Ascorbate and aldarate metabolism 8件: Ascorbate and aldarate metabolism, Biosynthesis of cofactors, Drug metabolism - other enzymes, Glycosaminoglycan degradation, Lysosome, Metabolic pathways, Pentose and glucuronate interconversions, Porphyrin and chlorophyll metabolism |
019 1件: 19 💬 |
474 |
Recombinant human beta-glucuronidase (rhgus) |
Vestronidase alfa |
1件: D11004 D11004 💬 |
GUSB 1件: GUSB 💬 |
Ascorbate and aldarate metabolism 8件: Ascorbate and aldarate metabolism, Biosynthesis of cofactors, Drug metabolism - other enzymes, Glycosaminoglycan degradation, Lysosome, Metabolic pathways, Pentose and glucuronate interconversions, Porphyrin and chlorophyll metabolism |
019 1件: 19 💬 |
475 |
Recombinant human betaglucuronidase |
- |
- |
- |
- |
019 1件: 19 💬 |
476 |
Recombinant human derived macrophage-targeted beta-glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
477 |
Recombinant human derived macrophage-targeted ß-glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
478 |
Recombinant human glucerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
479 |
Recombinant human glucocerebrosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
480 |
Recombinant human glucocerebrosidase (prgcd) |
Taliglucerase alfa |
1件: D09675 D09675 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
481 |
Recombinant human heparan n-sulfatase |
- |
- |
- |
- |
019 1件: 19 💬 |
482 |
Recombinant human heparan n-sulfatase (rhhns) |
- |
- |
- |
- |
019 1件: 19 💬 |
483 |
Recombinant human heparan n-sulfatase [rhhns] |
- |
- |
- |
- |
019 1件: 19 💬 |
484 |
Recombinant human heparan nsulfatase (rhhns) |
- |
- |
- |
- |
019 1件: 19 💬 |
485 |
Recombinant human lysosomal acid lipase |
- |
- |
- |
- |
019 1件: 19 💬 |
486 |
Recombinant human lysosomal acid lipase (rhlal) |
- |
- |
- |
- |
019 1件: 19 💬 |
487 |
Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa) |
Cholesterol |
1件: D00040 D00040 💬 |
- |
- |
019 1件: 19 💬 |
488 |
Recombinant human lysosomal acid lipase (rhlal), esterase, cholesterol (human gene lipa), lysosomal acid lipase (human gene lipa) |
Cholesterol |
1件: D00040 D00040 💬 |
- |
- |
019 1件: 19 💬 |
489 |
Recombinant human lysosomal alpha-mannosidase |
- |
- |
- |
- |
019 1件: 19 💬 |
490 |
Recombinant human n-acetylgalactosamine 4-sulfatase |
- |
- |
- |
- |
019 1件: 19 💬 |
491 |
Recombinant human n-acetylgalactosamine 6-sulfatase, bmn 110 |
- |
- |
- |
- |
019 1件: 19 💬 |
492 |
Recombinant human n-acetylgalactosamine 6-sulfatase, bmn 110 drug substance |
- |
- |
- |
- |
019 1件: 19 💬 |
493 |
Recombinant human n-acetylgalactosamine-6-sulfatase (rhgalns) |
Elosulfase alfa |
1件: D10333 D10333 💬 |
GALNS 1件: GALNS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
494 |
Recombinant human n-acetylgalactosamine-6-sulfatase, bmn 110 |
Elosulfase alfa |
1件: D10333 D10333 💬 |
GALNS 1件: GALNS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
495 |
Recombinant human n-acetylgalactosamine-6-sulfatase, bmn 110 drug substance |
Elosulfase alfa |
1件: D10333 D10333 💬 |
GALNS 1件: GALNS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
496 |
Recombinant human nacetylgalactosamine- |
- |
- |
- |
- |
019 1件: 19 💬 |
497 |
Recombinant human tripeptidyl peptidase-1 |
- |
- |
- |
- |
019 1件: 19 💬 |
498 |
Recombinant human tripeptidyl peptidase-1 (rhtpp1) |
- |
- |
- |
- |
019 1件: 19 💬 |
499 |
Reduced intensity conditioning |
- |
- |
- |
- |
019 2件: 19, 65 💬 |
500 |
Reminder capsules |
- |
- |
- |
- |
019 1件: 19 💬 |
501 |
Reminder product |
- |
- |
- |
- |
019 1件: 19 💬 |
502 |
Replagal |
- |
- |
- |
- |
019 1件: 19 💬 |
503 |
Replagal (agalsidase alfa) |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
504 |
Replagal agalsidase alfa |
Agalsidase alfa |
1件: D02784 D02784 💬 |
GLA 1件: GLA 💬 |
Galactose metabolism 6件: Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
505 |
Rh growth hormone |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
019 1件: 19 💬 |
506 |
Rharsa |
- |
- |
- |
- |
019 1件: 19 💬 |
507 |
Rhasa |
- |
- |
- |
- |
019 1件: 19 💬 |
508 |
Rhasm |
- |
- |
- |
- |
019 1件: 19 💬 |
509 |
Rhgus |
- |
- |
- |
- |
019 1件: 19 💬 |
510 |
Rhhns-10 mg |
- |
- |
- |
- |
019 1件: 19 💬 |
511 |
Rhhns-45 mg |
- |
- |
- |
- |
019 1件: 19 💬 |
512 |
Rhhns-90 mg |
- |
- |
- |
- |
019 1件: 19 💬 |
513 |
Rhidu (recombinant human-alpha-l-iduronidase) |
- |
- |
- |
- |
019 1件: 19 💬 |
514 |
Rhlaman |
Velmanase alfa |
1件: D11024 D11024 💬 |
MAN2B1 1件: MAN2B1 💬 |
Lysosome 2件: Lysosome, Other glycan degradation |
019 1件: 19 💬 |
515 |
Rhnaglu |
- |
- |
- |
- |
019 1件: 19 💬 |
516 |
Rhnaglu radiolabelled |
- |
- |
- |
- |
019 1件: 19 💬 |
517 |
Rhnaglu-igf2 |
- |
- |
- |
- |
019 1件: 19 💬 |
518 |
Rimiducid |
Rimiducid |
1件: D11195 D11195 💬 |
CASP9 1件: CASP9 💬 |
Alzheimer disease 34件: Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Colorectal cancer, Endometrial cancer, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Huntington disease, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Measles, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parkinson disease, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prion disease, Prostate cancer, Small cell lung cancer, Thyroid hormone signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Viral myocarditis, p53 signaling pathway |
019 6件: 19, 60, 65, 284, 285, 326 💬 |
519 |
Rituximab |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
011 47件: 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬 |
520 |
Rivogenlecleucel |
- |
- |
- |
- |
019 6件: 19, 60, 65, 284, 285, 326 💬 |
521 |
Rp 103 |
- |
- |
- |
- |
008 2件: 8 , 19 💬 |
522 |
Rp103 |
- |
- |
- |
- |
008 2件: 8 , 19 💬 |
523 |
Rvx000222 |
- |
- |
- |
- |
019 1件: 19 💬 |
524 |
Saf-301 |
- |
- |
- |
- |
019 1件: 19 💬 |
525 |
Saline solution for injection |
- |
- |
- |
- |
019 1件: 19 💬 |
526 |
Sar402671, gz402671 or gz/sar402671 |
- |
- |
- |
- |
006 3件: 6 , 19, 67 💬 |
527 |
Sb-318 |
- |
- |
- |
- |
019 1件: 19 💬 |
528 |
Sb-47171 |
- |
- |
- |
- |
019 1件: 19 💬 |
529 |
Sb-47898 |
- |
- |
- |
- |
019 1件: 19 💬 |
530 |
Sb-913 |
- |
- |
- |
- |
019 1件: 19 💬 |
531 |
Sb-a6p-hrl donor vector |
- |
- |
- |
- |
019 1件: 19 💬 |
532 |
Sb-fix |
- |
- |
- |
- |
019 1件: 19 💬 |
533 |
Sb-idua |
- |
- |
- |
- |
019 1件: 19 💬 |
534 |
Sbc-102 |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
535 |
Sbc-102, recombinant human lysosomal acid lipase |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
536 |
Sbc-103 |
- |
- |
- |
- |
019 1件: 19 💬 |
537 |
Scaav9.u1a.hsgsh |
- |
- |
- |
- |
019 1件: 19 💬 |
538 |
Scaav9.u1a.sgsh |
- |
- |
- |
- |
019 1件: 19 💬 |
539 |
Sebelipasa alfa |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
540 |
Sebelipase alfa |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
541 |
Sebelipase alfa (sbc-102) |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
542 |
Sebelipase alfa 0.35 mg/kg |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
543 |
Sebelipase alfa 1 mg/kg |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
544 |
Sebelipase alfa 3 mg/kg |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
545 |
Shp611 |
- |
- |
- |
- |
019 1件: 19 💬 |
546 |
Sirolimus |
Sirolimus |
1件: D00753 D00753 💬 |
MTOR 1件: MTOR 💬 |
AMPK signaling pathway 50件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
006 35件: 6 , 13, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 💬 |
547 |
Sobi003 |
- |
- |
- |
- |
019 1件: 19 💬 |
548 |
Sofosbuvir |
Sofosbuvir |
1件: D10366 D10366 💬 |
- |
- |
019 1件: 19 💬 |
549 |
Somatropin |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
002 16件: 2 , 3 , 19, 46, 74, 75, 78, 96, 113, 187, 193, 195, 265, 274, 276, 299 💬 |
550 |
Somatropin (dna origin) |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
019 1件: 19 💬 |
551 |
Ss-mercaptoethylamine hydrochloride & 2-aminoethanethiol hydrochloride |
Cysteamine |
2件: D03634 D03634, D03635 D03635 💬 |
- |
- |
019 1件: 19 💬 |
552 |
St-920 |
- |
- |
- |
- |
019 1件: 19 💬 |
553 |
Stem cell transplantation |
- |
- |
- |
- |
013 10件: 13, 19, 20, 46, 65, 90, 125, 164, 234, 326 💬 |
554 |
Sub195712 |
- |
- |
- |
- |
019 1件: 19 💬 |
555 |
Taliglucerase alfa |
Taliglucerase alfa |
1件: D09675 D09675 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
556 |
Taliglucerase alfa - recombinant human glucocerebrosidase |
Taliglucerase alfa |
1件: D09675 D09675 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
557 |
Tbd |
- |
- |
- |
- |
019 4件: 19, 86, 276, 299 💬 |
558 |
Thiotepa |
Thiotepa |
1件: D00583 D00583 💬 |
- |
- |
013 11件: 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284 💬 |
559 |
Thiotepa--escalated dose |
Thiotepa |
1件: D00583 D00583 💬 |
- |
- |
019 4件: 19, 20, 65, 284 💬 |
560 |
Thiotepa--single daily dose |
Thiotepa |
1件: D00583 D00583 💬 |
- |
- |
019 4件: 19, 20, 65, 284 💬 |
561 |
Thyroxine |
Levothyroxine |
2件: D01010 D01010, D08125 D08125 💬 |
THRA 2件: THRA, THRB 💬 |
Neuroactive ligand-receptor interaction 2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway |
019 1件: 19 💬 |
562 |
Trappsol cyclo |
- |
- |
- |
- |
019 1件: 19 💬 |
563 |
Treosulfan |
Treosulfan |
1件: D07253 D07253 💬 |
- |
- |
013 3件: 13, 19, 65 💬 |
564 |
Triapin |
- |
- |
- |
- |
019 1件: 19 💬 |
565 |
Triapin& triapin mite |
- |
- |
- |
- |
019 1件: 19 💬 |
566 |
Tropicamide |
Tropicamide |
1件: D00397 D00397 💬 |
CHRM1 5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
006 2件: 6 , 19 💬 |
567 |
Unrelated umbilical cord blood transplant |
- |
- |
- |
- |
019 1件: 19 💬 |
568 |
Uplyso |
- |
- |
- |
- |
019 1件: 19 💬 |
569 |
Usan: sebelipasa alfa |
Sebelipase alfa |
1件: D10377 D10377 💬 |
LIPA 1件: LIPA 💬 |
Cholesterol metabolism 3件: Cholesterol metabolism, Lysosome, Steroid biosynthesis |
019 1件: 19 💬 |
570 |
Usan: sebelipase alpha |
- |
- |
- |
- |
019 1件: 19 💬 |
571 |
Ux003 |
- |
- |
- |
- |
019 1件: 19 💬 |
572 |
Vector viral adenoasociado de serotipo 9 que contiene el gen de la sulfamidasa humana |
- |
- |
- |
- |
019 1件: 19 💬 |
573 |
Velaglucerase alfa |
Velaglucerase alfa |
1件: D09029 D09029 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
574 |
Velaglucerase alfa (vpriv) |
Velaglucerase alfa |
1件: D09029 D09029 💬 |
GBA 1件: GBA 💬 |
Lysosome 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism |
019 1件: 19 💬 |
575 |
Velaglucerasi alfa |
- |
- |
- |
- |
019 1件: 19 💬 |
576 |
Velmanase alfa |
Velmanase alfa |
1件: D11024 D11024 💬 |
MAN2B1 1件: MAN2B1 💬 |
Lysosome 2件: Lysosome, Other glycan degradation |
019 1件: 19 💬 |
577 |
Velmanase alfa (e.g. lamazym) |
Velmanase alfa |
1件: D11024 D11024 💬 |
MAN2B1 1件: MAN2B1 💬 |
Lysosome 2件: Lysosome, Other glycan degradation |
019 1件: 19 💬 |
578 |
Venglustat |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
006 3件: 6 , 19, 67 💬 |
579 |
Venglustat (gz/sar402671) |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
580 |
Venglustat gz402671 |
Venglustat |
1件: D11633 D11633 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 2件: 19, 67 💬 |
581 |
Vimizim® (elosulfase alfa) |
Elosulfase alfa |
1件: D10333 D10333 💬 |
GALNS 1件: GALNS 💬 |
Glycosaminoglycan degradation 3件: Glycosaminoglycan degradation, Lysosome, Metabolic pathways |
019 1件: 19 💬 |
582 |
Vitamin d |
Vitamin D |
- |
- |
- |
013 21件: 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 274, 298, 299 💬 |
583 |
Vorinostat |
Vorinostat |
1件: D06320 D06320 💬 |
HDAC1 11件: HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 💬 |
Alcoholism 17件: Alcoholism, Amphetamine addiction, Amyotrophic lateral sclerosis, Apelin signaling pathway, Cell cycle, Chronic myeloid leukemia, Epstein-Barr virus infection, Human papillomavirus infection, Huntington disease, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, Notch signaling pathway, Pathways in cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Viral carcinogenesis |
019 3件: 19, 75, 96 💬 |
584 |
Vpriv |
- |
- |
- |
- |
019 1件: 19 💬 |
585 |
Vpriv - 400 u - polvere per soluzione per infusione - uso endovenoso - flaconcino(vetro) 1 flaconcino |
- |
- |
- |
- |
019 1件: 19 💬 |
586 |
Vpriv 400 units powder for solution of infusion |
- |
- |
- |
- |
019 1件: 19 💬 |
587 |
Vpriv ®, |
- |
- |
- |
- |
019 1件: 19 💬 |
588 |
Vpriv® |
- |
- |
- |
- |
019 1件: 19 💬 |
589 |
Vts-270 |
- |
- |
- |
- |
019 1件: 19 💬 |
590 |
Warfarin |
Warfarin |
3件: D00564 D00564, D01280 D01280, D08682 D08682 💬 |
NQO1 2件: NQO1, VKORC1 💬 |
Biosynthesis of cofactors 6件: Biosynthesis of cofactors, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Metabolic pathways, Pathways in cancer, Ubiquinone and other terpenoid-quinone biosynthesis |
006 11件: 6 , 8 , 13, 19, 46, 49, 66, 85, 88, 96, 97 💬 |
591 |
Water |
Water |
1件: D00001 D00001 💬 |
- |
- |
002 22件: 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
592 |
Zavesca |
- |
- |
- |
- |
019 3件: 19, 256, 299 💬 |
593 |
Zavesca (miglustat) |
Miglustat |
1件: D05032 D05032 💬 |
UGCG 1件: UGCG 💬 |
Metabolic pathways 2件: Metabolic pathways, Sphingolipid metabolism |
019 1件: 19 💬 |
594 |
Zavesca 84cps 100mg |
- |
- |
- |
- |
019 1件: 19 💬 |
595 |
Zestoretic 10,20 |
- |
- |
- |
- |
019 1件: 19 💬 |
596 |
Zestoric |
- |
- |
- |
- |
019 1件: 19 💬 |
597 |
Zestril |
- |
- |
- |
- |
019 3件: 19, 67, 222 💬 |